Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

Project Summary/Abstract – Clinical Core (CC) The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection- specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically, the CC will: 1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART, Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to Cores/Projects for OMIC and immune assays; 2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and 3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins, metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future investigations.